Literature DB >> 10458566

Simultaneous superficial hyperthermia and external radiotherapy: report of thermal dosimetry and tolerance to treatment.

R J Myerson1, W L Straube, E G Moros, B N Emami, H K Lee, C A Perez, M E Taylor.   

Abstract

BACKGROUND: In vitro and animal studies indicate that a moderate temperature of 41 degrees C maintained for approximately 1 h will provide radiosensitization if radiation (RT) and hyperthermia (HT) are delivered simultaneously, but not with sequential treatment. A minimum tumour temperature of 41 degrees C is a more feasible goal than the goal of >42 degrees C needed for sequential treatment. METHODS AND MATERIALS: Forty-four patients with 47 recurrent superficial cancers received simultaneous external beam radiotherapy and superficial hyperthermia on successive IRB approved phase I/II studies. All lesions had failed previous therapy, 35 were previously irradiated (mean dose 52.7 Gy). Hyperthermia was delivered with 915 MHz microwave or 1-3.5 MHz ultrasound using commercially available applicators. The average dimensions of 19 lesions treated with microwave were 4.7 x 3.6 x 1.7 cm and the average dimensions of 28 lesions treated with ultrasound were 8.0 x 6.1 x 2.9 cm. The most common sites were chest wall (15 cases) and head and neck (21 cases). Temperatures were monitored at an average of six intratumoral locations using multisensor probes. The median number of hyperthermia treatments was three and the median radiation dose 30 Gy. Radiation dose per fraction was 4 Gy with hyperthermia and 2 Gy or 4 Gy (depending on protocol) on non-hyperthermia days.
RESULTS: Six different measures of minimum monitored temperature and duration were found to be highly correlated with each other. There was nearly a one-to-one correspondence between minimum tumour time at or above 41 degrees C (Min t41) and minimum tumour Sapareto Dewey equivalent time at 42 degrees C (Min teq42). After four sessions 63% of cases had a per session average Sapareto Dewey equivalent time at 41 degrees C which exceeded 60 min in all monitored tumour locations. The complete and partial response rate in evaluable lesions were respectively 21/41 (51%) and 7/41 (17%) and were best correlated with site (chest wall showing best response). Toxicity consisted of 10/47 (21%) slow healing soft tissue ulcers which healed in all cases but required a median of 7 months. The most important predictors for chronic ulceration were cumulative radiation dose >80 Gy and complete response to treatment.
CONCLUSIONS: Minimum tumour temperatures maintained for durations compatible in vitro with thermal radiosensitization (if RT and HT are delivered simultaneously) are clinically feasible and tolerable for broad but superficial lesions amenable to externally applied ultrasound or microwave hyperthermia. The current in-house protocol is evaluating the impact of more than four hyperthermia sessions on the overall thermal dose distribution and toxicity.

Entities:  

Mesh:

Year:  1999        PMID: 10458566     DOI: 10.1080/026567399285639

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  18 in total

1.  Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy.

Authors:  Timothy M Zagar; Kristin A Higgins; Edward F Miles; Zeljko Vujaskovic; Mark W Dewhirst; Robert W Clough; Leonard R Prosnitz; Ellen L Jones
Journal:  Radiother Oncol       Date:  2010-11-11       Impact factor: 6.280

Review 2.  Ultrasound Hyperthermia Technology for Radiosensitization.

Authors:  Lifei Zhu; Michael B Altman; Andrei Laszlo; William Straube; Imran Zoberi; Dennis E Hallahan; Hong Chen
Journal:  Ultrasound Med Biol       Date:  2019-02-14       Impact factor: 2.998

Review 3.  Sound waves and antineoplastic drugs: The possibility of an enhanced combined anticancer therapy.

Authors:  Loreto B Feril; Takashi Kondo; Shin-Ichiro Umemura; Katsuro Tachibana; Angelo H Manalo; Peter Riesz
Journal:  J Med Ultrason (2001)       Date:  2002-12       Impact factor: 1.314

4.  Progress on ThermoBrachytherapy Surface Applicator for Superficial Tissue Diseases.

Authors:  Kavitha Arunachalam; Oana I Craciunescu; Paolo F Maccarini; Jaime L Schlorff; Edward Markowitz; Paul R Stauffer
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2009-02-12

5.  Endocervical ultrasound applicator for integrated hyperthermia and HDR brachytherapy in the treatment of locally advanced cervical carcinoma.

Authors:  Jeffery H Wootton; I-Chow Joe Hsu; Chris J Diederich
Journal:  Med Phys       Date:  2011-02       Impact factor: 4.071

6.  Thermal characteristics of thermobrachytherapy surface applicators for treating chest wall recurrence.

Authors:  K Arunachalam; P F Maccarini; O I Craciunescu; J L Schlorff; P R Stauffer
Journal:  Phys Med Biol       Date:  2010-03-12       Impact factor: 3.609

Review 7.  Present and future technology for simultaneous superficial thermoradiotherapy of breast cancer.

Authors:  Eduardo G Moros; Jose Peñagaricano; Petr Novàk; William L Straube; Robert J Myerson
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

8.  Design of a water coupling bolus with improved flow distribution for multi-element superficial hyperthermia applicators.

Authors:  Kavitha Arunachalam; Paolo F Maccarini; Jaime L Schlorff; Yngve Birkelund; Svein Jacobsen; Paul R Stauffer
Journal:  Int J Hyperthermia       Date:  2009-11       Impact factor: 3.914

9.  Feasibility of concurrent treatment with the scanning ultrasound reflector linear array system (SURLAS) and the helical tomotherapy system.

Authors:  José A Peñagarícano; Eduardo Moros; Petr Novák; Yulong Yan; Peter Corry
Journal:  Int J Hyperthermia       Date:  2008-08       Impact factor: 3.914

10.  Simultaneous radiotherapy and superficial hyperthermia for high-risk breast carcinoma: a randomised comparison of treatment sequelae in heated versus non-heated sectors of the chest wall hyperthermia.

Authors:  Sumeeta Varma; Robert Myerson; Eduardo Moros; Marie Taylor; William Straube; Imran Zoberi
Journal:  Int J Hyperthermia       Date:  2012-09-04       Impact factor: 3.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.